Display options
Cite
Alunni-Fabbroni M, Müller V, Fehm T, et al. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014;9(1):16-21doi: 10.1159/000360438.
Alunni-Fabbroni, M., Müller, V., Fehm, T., Janni, W., & Rack, B. (2014). Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast care (Basel, Switzerland), 9(1), 16-21. https://doi.org/10.1159/000360438
Alunni-Fabbroni, Marianna, et al. "Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?." Breast care (Basel, Switzerland) vol. 9,1 (2014): 16-21. doi: https://doi.org/10.1159/000360438
Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438. PMID: 24803882; PMCID: PMC3995372.
Copy Download .nbib Format: NLM
Share it on

Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438.

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?.

Breast care (Basel, Switzerland)

Marianna Alunni-Fabbroni, Volkmar Müller, Tanja Fehm, Wolfgang Janni, Brigitte Rack

Affiliations

  1. Clinic for Gynecology and Obstetrics, Ludwig-Maximilians University, Munich, Germany.
  2. Clinic for Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Germany.
  3. Clinic for Gynecology and Obstetrics, Heinrich-Heine-University, Düsseldorf, Germany.
  4. Clinic for Gynecology and Obstetrics, University Hospital Ulm, Germany.

PMID: 24803882 PMCID: PMC3995372 DOI: 10.1159/000360438

Abstract

In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment are required before these technologies can offer any reliable information on effective disease regression, and, in the meanwhile, the patients are exposed to potentially unnecessary therapy. Circulating tumor cells (CTCs) have been shown to be powerful prognostic and predictive markers and provide clinicians with valuable information. However, in one clinical trial, an early change of chemotherapy based on CTC detection did not result in improved survival. Currently, CTC detection outside clinical trials should be limited to selected clinical situations, i.e. increased treatment toxicity or as risk estimation.

Keywords: Breast cancer; Circulating tumor cells; Imaging; MRI; Metastatic breast cancer; Minimal residual disease; PET/CT

References

  1. N Engl J Med. 2000 Feb 24;342(8):525-33 - PubMed
  2. Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 - PubMed
  3. Breast. 2013 Jun;22(3):203-10 - PubMed
  4. Clin Cancer Res. 2007 Feb 1;13(3):920-8 - PubMed
  5. Clin Exp Metastasis. 2008;25(8):871-5 - PubMed
  6. Cancer Immunol Immunother. 2013 May;62(5):931-9 - PubMed
  7. World J Clin Oncol. 2011 Apr 10;2(4):171-8 - PubMed
  8. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  9. J Clin Oncol. 2005 Mar 1;23(7):1420-30 - PubMed
  10. Ann Oncol. 2012 Mar;23(3):618-624 - PubMed
  11. Breast Cancer. 2010 Jul;17(3):199-204 - PubMed
  12. Cancer Biomark. 2010;9(1-6):7-20 - PubMed
  13. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 - PubMed
  14. Radiology. 2008 Apr;247(1):189-96 - PubMed
  15. J Nucl Med. 2010 Aug;51(8):1213-8 - PubMed
  16. N Engl J Med. 2004 Aug 19;351(8):781-91 - PubMed
  17. Cancer. 2000 May 15;88(10):2252-9 - PubMed
  18. Nat Rev Cancer. 2007 Nov;7(11):834-46 - PubMed
  19. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  20. Clin Cancer Res. 2006 Nov 1;12(21):6403-9 - PubMed
  21. Breast Cancer Res. 2012 Aug 15;14(4):R118 - PubMed
  22. J Clin Oncol. 1991 Oct;9(10):1749-56 - PubMed
  23. Ann Oncol. 2010 Jan;21(1):33-9 - PubMed
  24. Cancer Causes Control. 2012 Jan;23(1):103-12 - PubMed
  25. Cancer Metastasis Rev. 2013 Jun;32(1-2):179-88 - PubMed
  26. Gynecol Oncol. 2011 Aug;122(2):356-60 - PubMed
  27. Mol Oncol. 2008 Aug;2(2):115-52 - PubMed
  28. Clin Chem. 2006 Mar;52(3):345-51 - PubMed
  29. Radiology. 2004 May;231(2):305-32 - PubMed
  30. Clin Imaging. 2013 May-Jun;37(3):420-6 - PubMed
  31. J Clin Oncol. 2002 Jan 15;20(2):379-87 - PubMed
  32. Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9 - PubMed
  33. Cell. 2009 Dec 24;139(7):1315-26 - PubMed
  34. J Clin Oncol. 2009 Nov 1;27(31):5153-9 - PubMed
  35. Eur J Radiol. 1998 May;27 Suppl 2:S149-56 - PubMed
  36. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24 - PubMed
  37. Cancer. 2008 Nov 1;113(9):2422-30 - PubMed
  38. Ann Diagn Pathol. 2011 Apr;15(2):79-83 - PubMed
  39. J Nucl Med. 2011 Oct;52(10):1501-4 - PubMed
  40. Annu Rev Med. 2012;63:199-215 - PubMed
  41. Am J Pathol. 2013 Oct;183(4):1075-1083 - PubMed
  42. J Nucl Med. 2005 Jul;46(7):1144-50 - PubMed
  43. Semin Nucl Med. 2010 Jul;40(4):283-93 - PubMed
  44. Ann Oncol. 2013 Nov;24(11):2766-72 - PubMed
  45. Cancer Res. 2004 Aug 15;64(16):5818-24 - PubMed
  46. Health Technol Assess. 2013 Apr;17(16):1-243 - PubMed
  47. J Cancer Res Clin Oncol. 2011 Nov;137(11):1595-605 - PubMed
  48. Breast Cancer Res. 2010;12(2):304 - PubMed
  49. J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8 - PubMed
  50. Anticancer Res. 2011 Sep;31(9):2749-55 - PubMed
  51. Mol Cancer Ther. 2012 Nov;11(11):2526-34 - PubMed
  52. Clin Oncol (R Coll Radiol). 2013 Feb;25(2):93-100 - PubMed
  53. Nat Rev Cancer. 2004 Jun;4(6):448-56 - PubMed
  54. Semin Nucl Med. 2013 Jul;43(4):317-23 - PubMed
  55. J Cancer Res Clin Oncol. 2013 Jun;139(6):1055-62 - PubMed
  56. Breast Cancer Res Treat. 2013 Jan;137(2):503-10 - PubMed
  57. J Clin Oncol. 2009 Jul 10;27(20):3303-11 - PubMed
  58. Ann Oncol. 2008 May;19(5):891-7 - PubMed
  59. Radiology. 2012 Jan;262(1):374; author reply 374 - PubMed
  60. Clin Chem. 2013 Jan;59(1):110-8 - PubMed
  61. BMC Cancer. 2006 Jul 06;6:179 - PubMed
  62. Nucl Med Commun. 2002 Jul;23(7):613-8 - PubMed

Publication Types